Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HIV/AIDS Dietary Supplement Research Sponsored By NCCAM, NINR

This article was originally published in The Tan Sheet

Executive Summary

NCCAM is looking to fund research on the properties of botanicals used by HIV/AIDS patients, including their potential antiretroviral properties as well as their ability to alleviate the side effects of HIV/AIDS drugs or to interact with such drugs

You may also be interested in...



Protocol Review, Clinical Trial Conduct Purview Of New NCCAM Office

NCCAM's Office of Clinical & Regulatory Affairs expects to use an FDA draft guidance on botanical drug products as a starting point for reviewing research protocols and overseeing clinical trials funded by the center, OCRA Director Jonathan Berman, MD/PhD, said Aug. 26

Protocol Review, Clinical Trial Conduct Purview Of New NCCAM Office

NCCAM's Office of Clinical & Regulatory Affairs expects to use an FDA draft guidance on botanical drug products as a starting point for reviewing research protocols and overseeing clinical trials funded by the center, OCRA Director Jonathan Berman, MD/PhD, said Aug. 26

Protocol Review, Clinical Trial Conduct Purview Of New NCCAM Office

NCCAM's Office of Clinical & Regulatory Affairs expects to use an FDA draft guidance on botanical drug products as a starting point for reviewing research protocols and overseeing clinical trials funded by the center, OCRA Director Jonathan Berman, MD/PhD, said Aug. 26

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel